InnaVirVax SA, a biopharmaceutical company specialised in the research and development of therapeutic and diagnostic innovations focused on immune dysregulation, today announced that its leadership of the PROTEVIH consortium, which is being funded by the French public agency Bpifrance under its Strategic Industrial Innovation programme.
http://ift.tt/1pK8kmS
http://ift.tt/1pK8kmS
No comments:
Post a Comment